PriceTargets.com logo

C4 Therapeutics - CCCC Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $10.67
  • Forecasted Upside: 170.04%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.95 As of 12/20/2024 06:31 PM ET
▲ +0.1 (2.60%)

This chart shows the closing price for CCCC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New C4 Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CCCC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CCCC

Analyst Price Target is $10.67
▲ +170.04% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for C4 Therapeutics in the last 3 months. The average price target is $10.67, with a high forecast of $20.00 and a low forecast of $4.00. The average price target represents a 170.04% upside from the last price of $3.95.

This chart shows the closing price for CCCC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 polled investment analysts is to moderate buy stock in C4 Therapeutics. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/19/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$8.00 ➝ $12.00
11/18/2024StephensInitiated CoverageEqual Weight$4.00
8/6/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$20.00 ➝ $20.00
5/9/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$7.00 ➝ $8.00
5/9/2024Stifel NicolausBoost TargetBuy ➝ Buy$13.00 ➝ $14.00
2/26/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$8.00
2/23/2024Stifel NicolausReiterated RatingBuy ➝ Buy$12.00 ➝ $13.00
1/29/2024JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$6.00
12/13/2023Stifel NicolausUpgradeHold ➝ Buy$2.00 ➝ $12.00
11/6/2023Morgan StanleyUpgradeUnderweight ➝ Equal Weight
11/3/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$18.00 ➝ $16.00
11/2/2023HC WainwrightLower TargetBuy ➝ Buy$17.00 ➝ $7.00
10/9/2023Bank of AmericaLower TargetNeutral ➝ Neutral$5.00 ➝ $2.00
8/9/2023HC WainwrightLower TargetBuy ➝ Buy$25.00 ➝ $17.00
7/21/2023UBS GroupLower Target$22.00 ➝ $20.00
5/30/2023Evercore ISILower Target$10.00
5/8/2023HC WainwrightLower Target$35.00 ➝ $25.00
3/28/2023Bank of AmericaLower TargetNeutral$11.00 ➝ $5.00
2/27/2023Morgan StanleyLower TargetUnderweight$6.00 ➝ $5.00
2/24/2023Credit Suisse GroupUpgradeUnderperform ➝ Neutral$12.00 ➝ $10.00
2/24/2023HC WainwrightReiterated RatingBuy$35.00
2/24/2023JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$15.00 ➝ $5.00
1/3/2023Wells Fargo & CompanyLower TargetEqual Weight$11.00 ➝ $9.00
11/8/2022Wells Fargo & CompanyLower TargetEqual Weight$12.00 ➝ $11.00
11/4/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$22.00 ➝ $15.00
10/26/2022Leerink PartnersReiterated RatingOutperform
10/11/2022Morgan StanleyInitiated CoverageUnderweight$6.00
8/9/2022Credit Suisse GroupBoost Target$12.00
5/9/2022HC WainwrightLower Target$63.00 ➝ $35.00
5/5/2022Stifel NicolausLower Target$15.00 ➝ $14.00
4/28/2022Credit Suisse GroupInitiated CoverageUnderperform$10.00
4/18/2022UBS GroupLower TargetBuy$64.00 ➝ $26.00
4/11/2022BMO Capital MarketsLower TargetOutperform$57.00 ➝ $20.00
4/11/2022Stifel NicolausLower Target$28.00 ➝ $15.00
4/10/2022Bank of AmericaDowngradeBuy ➝ Neutral$46.00 ➝ $15.00
3/10/2022JPMorgan Chase & Co.Initiated CoverageOverweight$43.00
2/10/2022Wells Fargo & CompanyInitiated CoverageEqual Weight$25.00
11/23/2021Bank of AmericaInitiated CoverageBuy$54.00
10/14/2021Leerink PartnersInitiated CoverageMarket Perform$20.00
9/29/2021Stifel NicolausInitiated CoverageHold$45.00
6/25/2021Brookline Capital ManagementReiterated RatingBuy
6/24/2021Brookline Capital AcquisitionInitiated CoverageBuy$54.00
6/22/2021BMO Capital MarketsBoost TargetOutperform$53.00 ➝ $55.00
6/4/2021HC WainwrightInitiated CoverageBuy$63.00
3/31/2021BMO Capital MarketsInitiated CoverageOutperform$55.00
12/8/2020BMO Capital MarketsBoost TargetOutperform$33.00 ➝ $45.00
10/28/2020UBS GroupInitiated CoverageBuy
10/27/2020Jefferies Financial GroupInitiated CoverageBuy$34.00
10/27/2020BMO Capital MarketsInitiated CoverageOutperform$33.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.69 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 4 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 4 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

C4 Therapeutics logo
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $3.95
Low: $3.72
High: $3.98

50 Day Range

MA: $5.04
Low: $3.65
High: $7.00

52 Week Range

Now: $3.95
Low: $3.61
High: $11.88

Volume

3,811,127 shs

Average Volume

2,089,906 shs

Market Capitalization

$278.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.92

Frequently Asked Questions

What sell-side analysts currently cover shares of C4 Therapeutics?

The following sell-side analysts have issued reports on C4 Therapeutics in the last twelve months: BMO Capital Markets, JPMorgan Chase & Co., Morgan Stanley, Stephens, Stifel Nicolaus, and Wells Fargo & Company.
View the latest analyst ratings for CCCC.

What is the current price target for C4 Therapeutics?

0 Wall Street analysts have set twelve-month price targets for C4 Therapeutics in the last year. Their average twelve-month price target is $10.67, suggesting a possible upside of 170.0%. BMO Capital Markets has the highest price target set, predicting CCCC will reach $20.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $4.00 for C4 Therapeutics in the next year.
View the latest price targets for CCCC.

What is the current consensus analyst rating for C4 Therapeutics?

C4 Therapeutics currently has 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CCCC.

What other companies compete with C4 Therapeutics?

Other companies that are similar to C4 Therapeutics include Calliditas Therapeutics AB (publ), ARS Pharmaceuticals, Syndax Pharmaceuticals, ANI Pharmaceuticals and Rocket Pharmaceuticals. Learn More about companies similar to C4 Therapeutics.

How do I contact C4 Therapeutics' investor relations team?

The company's listed phone number is 617-231-0700 and its investor relations email address is [email protected]. The official website for C4 Therapeutics is www.c4therapeutics.com. Learn More about contacing C4 Therapeutics investor relations.